Glukoza Baxter

Glukoza Baxter is an intravenous preparation that contains glucose monohydrate as its sole active ingredient. The product is supplied in a sterile solution form, with the specific concentration not disclosed, and is marketed within the European Union. It is classified as an excipient and serves as an intravenous solvent used to provide a source of carbohydrate energy during medical procedures. It may be used when rapid carbohydrate supplementation is needed.

Glukoza Baxter is employed as an intravenous carbohydrate source in various clinical settings where rapid glucose delivery is required. Its primary purpose is to supplement energy stores, support metabolic function, and assist in the management of low blood sugar during medical care.

- Correction of acute hypoglycemia in hospitalized patients. - Provision of caloric support during surgery or anesthesia. - Maintenance of blood glucose levels in patients receiving parenteral nutrition. - Dilution and carrier solution for compatible intravenous medications. - Rehydration support when combined with electrolytes in fluid therapy.

Glukoza Baxter, as an intravenous glucose solution, may be associated with a range of adverse reactions that vary in frequency and severity.

Common: - Mild hyperglycemia, characterized by a modest rise in blood glucose levels, may occur shortly after the infusion. - Transient nausea or occasional vomiting can be experienced during or shortly after administration. - Local irritation at the infusion site, presenting as mild redness or discomfort, is occasionally reported. - Mild electrolyte shifts, such as slight changes in serum potassium or sodium concentrations, may be observed.

Serious: - Severe hyperglycemia that progresses to osmotic diuresis, potentially leading to dehydration and electrolyte imbalance. - Allergic or anaphylactic reactions, including rash, itching, swelling, or respiratory distress, may develop in hypersensitive individuals. - Volume overload, which can precipitate pulmonary edema especially in patients with compromised cardiac function, is a serious concern.

When using Glukoza Baxter, clinicians should observe several precautionary measures to minimize risks and ensure appropriate patient management.

- Assess baseline blood glucose and monitor levels frequently during infusion. - Evaluate cardiac and renal function before administration, especially in patients at risk of fluid overload. - Avoid use in individuals with known hypersensitivity to glucose solutions or excipients. - Adjust infusion rate in patients with diabetes or impaired glucose tolerance. - Consider electrolyte status and correct abnormalities prior to initiating therapy. - Use caution in neonates and pediatric patients due to differing metabolic needs. - Document infusion details and any adverse reactions in the patient’s medical record.

Glukoza Baxter may interact with certain medications or clinical conditions, influencing its safety or efficacy when administered intravenously.

Avoid: - Concurrent administration with high-dose insulin without glucose monitoring, which can precipitate severe hypoglycemia. - Co-infusion with hyperosmolar solutions that may increase the risk of fluid overload. - Mixing with calcium-containing solutions, which can cause precipitation and compromise infusion safety.

Use with caution: - Simultaneous use with diuretics, as rapid glucose shifts can affect electrolyte balance. - Combination with medications that affect renal function, requiring close monitoring of fluid status. - Administration alongside catecholamines, which may alter glucose metabolism and require dose adjustments.